Media
OrganaBio and RxMP Therapeutics Announce Manufacturing Partnership to Advance RMP-402 Hemostatic Drug Product
MIAMI & SANTA FE, Calif.--(BUSINESS WIRE)--OrganaBio, LLC ("OrganaBio"), a vertically integrated blood and cell products and services company delivering end-to-end solutions for cell and gene therapy developers, and RxMP Therapeutics, Inc. ("RxMP"), a late pre-clinical development stage therapeutics company developing novel therapies for the rapid control of severe hemorrhage, today announced a manufacturing partnership under which OrganaBio will serve as RxMP's contract manufacturing partner for the cGMP production of its lead product candidate, RMP-402.
RxMP Therapeutics Announces Opening of $2 Million Bridge Financing Round
RxMP Therapeutics is announcing the opening of a $2 million bridge financing round to support the next phase of development for its lead hemostatic platform. The round already has over $1.2M committed, led by a $750,000 investment from the Wallace H. Coulter Foundation, the company’s largest shareholder and long-time partner. This strong early support, including additional investment in this round by insiders, underscores continued confidence in RxMP’s mission and progress toward delivering a life-saving hemorrhage control solution.
RxMP Press Release for Monday, June 9th, 2025
Enters Into Research & Development Agreement with Department of Defense’s Institute of Surgical Research
Reaches Consensus with FDA on GMP Allogeneic Manufacturing Process of RMP-402
Appoints Shawna Khouri as Chief Operating Officer